國立虎尾科技大學 |

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates./
Author:	Huang, Zhouyang.
Description:	1 online resource (244 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 85-03, Section: B.
Contained By:	Dissertations Abstracts International85-03B.
Subject:	Inorganic chemistry. -
Online resource:	click for full text (PQDT)
ISBN:	9798380314169

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.
Huang, Zhouyang.

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates. - 1 online resource (244 pages)

Source: Dissertations Abstracts International, Volume: 85-03, Section: B.

Thesis (Ph.D.)--Cornell University, 2023.

Includes bibliographical references

The clinical success of cisplatin and other platinum-based chemotherapeutics has inspired extensive research efforts to develop alternative metallodrugs with improved pharmacological properties. The first section of this dissertation focuses on design of novel metallodrugs for cytotoxic anticancer applications. Recently, rhenium(I) tricarbonyl complexes have attracted significant attention as novel anticancer agents, because their mechanisms of action are distinct from the DNA-binding pathways that are operative for platinum(II) complexes. Chapter 1 is a comprehensive review of the recent developments of multimetallic rhenium(I) tricarbonyl complexes for therapeutic and diagnostic applications. Chapter 2 describes the development of the first Pt(IV)Re(I) molecular conjugates as photoactivated anticancer agents.The second section of this dissertation explores the use of metal complexes as cytoprotective agents targeting the mitochondrial calcium uniporter (MCU), a transmembrane protein that is responsible for shuttling cytosolic Ca2+ into mitochondria. Dysregulation of the MCU can trigger an overload of mitochondrial Ca2+, which is implicated in the progression of cardiovascular and neurodegenerative diseases. As such, the chemical inhibition of MCU represents a promising therapeutic strategy. Chapter 3 summarizes recent advances in metal-based MCU inhibitors and highlights a diruthenium coordination complex, Ru265, as the state-of-the-art MCU inhibitor due to its excellent potency, selectivity, and cellular permeability. Chapter 3 also outlines the structure-activity relationship of Ru265-based MCU inhibitors. Chapter 4 describes a ferrocene-functionalized analogue of Ru265 and demonstrates that the cellular permeability of this class of MCU inhibitors can be rationally improved through ligand functionalization. Finally, Chapter 5 details the development of the first fluorogenic MCU inhibitor, a coumarin-functionalized analogue of Ru265.Collectively, these results demonstrate the potential of metal complexes for cytotoxic and cytoprotective applications and provide strategies for the rational design of metallodrug candidates.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798380314169Subjects--Topical Terms:

1182077
Inorganic chemistry.
Subjects--Index Terms:

RheniumIndex Terms--Genre/Form:

554714
Electronic books.

Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.
LDR:03477ntm a22003857 4500 001 1142056
005 20240414211933.5
006 m o d
007 cr mn ---uuuuu
008 250605s2023 xx obm 000 0 eng d
020 $a 9798380314169
035 $a (MiAaPQ)AAI30527302
035 $a AAI30527302
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Huang, Zhouyang. $3 1466206
245 1 0 $a Development of Rhenium, Platinum, and Ruthenium Metallodrug Candidates.
264 0 $c 2023
300 $a 1 online resource (244 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-03, Section: B.
500 $a Advisor: Wilson, Justin.
502 $a Thesis (Ph.D.)--Cornell University, 2023.
504 $a Includes bibliographical references
520 $a The clinical success of cisplatin and other platinum-based chemotherapeutics has inspired extensive research efforts to develop alternative metallodrugs with improved pharmacological properties. The first section of this dissertation focuses on design of novel metallodrugs for cytotoxic anticancer applications. Recently, rhenium(I) tricarbonyl complexes have attracted significant attention as novel anticancer agents, because their mechanisms of action are distinct from the DNA-binding pathways that are operative for platinum(II) complexes. Chapter 1 is a comprehensive review of the recent developments of multimetallic rhenium(I) tricarbonyl complexes for therapeutic and diagnostic applications. Chapter 2 describes the development of the first Pt(IV)Re(I) molecular conjugates as photoactivated anticancer agents.The second section of this dissertation explores the use of metal complexes as cytoprotective agents targeting the mitochondrial calcium uniporter (MCU), a transmembrane protein that is responsible for shuttling cytosolic Ca2+ into mitochondria. Dysregulation of the MCU can trigger an overload of mitochondrial Ca2+, which is implicated in the progression of cardiovascular and neurodegenerative diseases. As such, the chemical inhibition of MCU represents a promising therapeutic strategy. Chapter 3 summarizes recent advances in metal-based MCU inhibitors and highlights a diruthenium coordination complex, Ru265, as the state-of-the-art MCU inhibitor due to its excellent potency, selectivity, and cellular permeability. Chapter 3 also outlines the structure-activity relationship of Ru265-based MCU inhibitors. Chapter 4 describes a ferrocene-functionalized analogue of Ru265 and demonstrates that the cellular permeability of this class of MCU inhibitors can be rationally improved through ligand functionalization. Finally, Chapter 5 details the development of the first fluorogenic MCU inhibitor, a coumarin-functionalized analogue of Ru265.Collectively, these results demonstrate the potential of metal complexes for cytotoxic and cytoprotective applications and provide strategies for the rational design of metallodrug candidates.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Inorganic chemistry. $3 1182077
650 4 $a Chemistry. $3 593913
650 4 $a Biochemistry. $3 582831
653 $a Rhenium
653 $a Platinum
653 $a Ruthenium
653 $a Metallodrug candidates
655 7 $a Electronic books. $2 local $3 554714
690 $a 0488
690 $a 0487
690 $a 0485
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Cornell University. $b Chemistry and Chemical Biology. $3 1190331
773 0 $t Dissertations Abstracts International $g 85-03B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30527302 $z click for full text (PQDT)